GLUT 1 expression is a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma.
This study will investigate the phenotype of Glucose transporter 1 (GLUT1) in endometrial cancer and the association of its expression with tumor's clinicopathological factors. Standard immunohistochemistry (IHC) staining protocol was utilized to identify the location and expression pattern of GLUT1 in a panel of 71 endometrial carcinomas compared to 30 normal tissues using tissue microarrays. High scores of GLUT1 staining are more frequent in cancer cases, it was recognized in 64 (90%) endometrial cancers and 12 (40%) control cases. Tissue histotype (cancer versus non-cancerous) was associated with IHC staining of GLUT1 (p = 0.000). Significant association between strong GLUT1 staining of malignant epithelial cells and stage of tumor (p = 0.000) was observed, advanced disease stages were more prevalent with high GLUT1 staining in malignant epithelial cells. There is also a significant association between high scores of GLUT1 staining and location of expression in transformed epithelium, cytoplasmic and membranous (p = 0.000), 100% of cases with cytoplasmic and membranous expression showed high GLUT1 staining scores. Considerable varied survival models were observed with positive GLUT 1 neoplasm regarding diagnosis, grade, stage, differentiation, and recurrence (p-values 0.000, 0.000, 0.000, 0.002, and 0.000 respectively). Survival estimates are considerably healthier in positive GLUT1 staining cases of endometrial carcinoma, which have low grade, low stage and no recurrence. GLUT1 expression has been found upregulated in endometrial carcinoma. IHC staining of GLUT1 can be a supportive mean in predicting prognosis and survival estimates of endometrial carcinoma with specific clinical factors.